FDA Approves Miplyffa for Treatment of Niemann-Pick Disease, Type C
By Lori Solomon HealthDay Reporter
MONDAY, Sept. 30, 2024 -- The U.S. Food and Drug Administration has approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).
Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged 2 years and older. The approval received priority review, orphan drug, rare pediatric disease, fast track, and breakthrough therapy designations.
The approval is based on results from a randomized, double-blind, placebo-controlled 12-month trial in patients (ages 2 to 19 years) with a molecularly confirmed diagnosis of NPC. The analysis included 50 patients randomly assigned (2:1) to treatment with weight-adjusted Miplyffa (31 to 124 mg) or placebo orally three times per day. Miplyffa resulted in slower disease progression as measured by the rescored four-domain NPC Clinical Severity Scale score. The most common side effects of Miplyffa treatment included upper respiratory tract infection, diarrhea, and decreased weight.
"The first-ever approval of a safe and effective drug option for NPC will undoubtedly support the essential medical needs of those suffering," Janet Maynard, M.D., director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA Center for Drug Evaluation and Research, said in a statement.
Approval of Miplyffa was granted to Zevra Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.